Marquette Asset Management’s Arcturus Therapeutics ARCT Stock Holding History

Marquette Asset Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$671	Buy	+49	New	+$512	﹤0.01%	700

Other funds holding ARCT

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

GAA

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Marquette Asset Management's ARCT Position: Q3 2026 in Review

Marquette Asset Management opened a new position in Arcturus Therapeutics (ARCT) in Q3 2026: 49 shares worth $671. The stake represents ﹤0.01% of the portfolio and ranks #700 among its holdings.

10 funds tracked by Wall St. Rank hold ARCT as of Q3 2026.

Marquette Asset Management held 49 shares of Arcturus Therapeutics worth $671 as of Q3 2026.
Arcturus Therapeutics was a new Marquette Asset Management position in Q3 2026.
Arcturus Therapeutics made up ﹤0.01% of Marquette Asset Management's portfolio in Q3 2026, its #700 holding.
10 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2026.

Based on Marquette Asset Management's 13F filing for Q3 2026, filed 9 Oct 2026.